CSTLCastle Biosciences, Inc.

$805M

Q1 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$42M+56.6% YoY

Gross Profit

$32M75.8% margin

Operating Income

-$32M-75.0% margin

Net Income

-$29M-69.5% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$29M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$427M

Total Liabilities

$42M

Stockholders' Equity

$385M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$27M	+56.6%
Gross Profit	$32M	$21M	+52.4%
Operating Income	-$32M	-$25M	-28.6%
Net Income	-$29M	-$25M	-18.6%

Revenue Segments

Dermatologic

$36M100%

CSTL Q1 2023 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena